Artelo Biosciences Stock Price, News & Analysis

Artelo Biosciences, Inc. (NASDAQ: ARTL) is a clinical-stage pharmaceutical company focused on the development and commercialization of proprietary therapeutics that modulate lipid-signaling pathways, including the endocannabinoid system. According to the company’s public disclosures, Artelo is advancing a diversified pipeline that addresses significant unmet medical needs in anorexia, cancer, anxiety, dermatologic conditions, pain, and inflammation.

Artelo is incorporated in Nevada and its common stock trades on the Nasdaq Capital Market under the symbol ARTL. The company describes itself as a clinical-stage biopharmaceutical organization, applying scientific, regulatory, commercial, and treasury management practices, including the use of digital assets, to support its development programs and corporate objectives.

Business Focus and Therapeutic Strategy

Artelo’s core strategy centers on targeting lipid-signaling modulation pathways, with particular emphasis on the endocannabinoid system (ECS), a network of receptors and neurotransmitters involved in biochemical communication throughout the body. The company’s product candidate pipeline is designed to leverage these mechanisms across multiple indications where dysregulated lipid signaling is implicated, such as cancer, neuropathic and nociceptive pain, anxiety disorders, dermatologic conditions, and inflammatory states.

In its SEC registration materials, Artelo characterizes itself as a clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutics that target lipid-signaling modulation pathways, including the ECS. The company notes that its pipeline balances risk across mechanisms of action and stages of development.

Key Pipeline Programs

Artelo has publicly highlighted several proprietary programs that illustrate its approach to lipid-signaling and cannabinoid-related therapeutics:

• ART27.13 – Cancer Anorexia-Cachexia Syndrome (CACS)
  ART27.13 is described as a novel benzimidazole derivative and dual cannabinoid agonist being developed as a once-daily, orally administered agent that selectively targets peripheral CB1 and CB2 receptors. The company is evaluating ART27.13 as a supportive care therapy for cancer patients suffering from anorexia and weight loss, including those with cancer anorexia-cachexia syndrome. Artelo reports that ART27.13 has been studied in multiple clinical trials, including a Phase 1/2 randomized, placebo-controlled trial known as the Cancer Appetite Recovery Study (CAReS), which is designed to assess effects on weight, lean body mass, appetite, activity, and quality of life in patients who have experienced significant weight loss.
• ART26.12 – Fatty Acid Binding Protein 5 (FABP5) Inhibitor
  ART26.12 is Artelo’s lead Fatty Acid Binding Protein 5 (FABP5) inhibitor. The company describes it as a novel, peripherally acting, non-opioid, non-steroidal analgesic initially under development for chemotherapy-induced peripheral neuropathy (CIPN), under an investigational new drug application with the U.S. Food and Drug Administration. Artelo states that fatty acid binding proteins are intracellular proteins that chaperone lipids important to normal cellular function and that FABP is overexpressed and associated with abnormal lipid signaling in several pathologies. In addition to CIPN, Artelo’s library of small-molecule FABP inhibitors has shown therapeutic promise in preclinical research for certain cancers, neuropathic and nociceptive pain, psoriasis, and anxiety disorders.
• ART12.11 – Cannabidiol (CBD) Cocrystal
  ART12.11 is described as Artelo’s wholly owned, proprietary cocrystal composition of cannabidiol (CBD) and tetramethylpyrazine (TMP). The company reports that ART12.11 is isolated as a single crystalline form and has exhibited better pharmacokinetics and improved efficacy compared to other forms of CBD in nonclinical studies. Artelo highlights enhanced pharmaceutical properties, including physicochemical, pharmacokinetic, and pharmacodynamic advantages, and believes that a more consistent and improved bioavailability profile may translate into increased safety and efficacy in humans. The company further notes that ART12.11 is a non-controlled cocrystal composition and that, due to its crystalline structure and cocrystallization process, no THC or other controlled substances have been detected in ART12.11. A U.S. composition-of-matter patent for ART12.11 has been issued and, according to the company, has been granted or validated in multiple additional countries.
• FABP Inhibitor Platform and Oncology Research
  Artelo has disclosed a broader portfolio of selective, dual, and pan inhibitors targeting FABP3, FABP5, and FABP7. Peer-reviewed publications involving Artelo scientists and collaborators describe the emerging role of these FABP isoforms in cancer biology, including their association with tumor progression, lipid metabolism, hypoxia, and ferroptosis. Genetic and pharmacologic inhibition of FABP3, FABP5, and FABP7 in preclinical models has demonstrated therapeutic potential, supporting Artelo’s continued exploration of FABP inhibitors across oncology and other diseases linked to dysregulated lipid signaling.

Therapeutic Areas and Unmet Needs

Across its programs, Artelo emphasizes indications with significant unmet medical need. In public communications, the company highlights:

• Cancer anorexia-cachexia syndrome (CACS), a condition characterized by appetite loss, weight loss, and breakdown of muscle and fat in people with advanced cancer, for which there are no approved treatments in major markets referenced by the company.
• Chemotherapy-induced peripheral neuropathy (CIPN), a painful and often dose-limiting side effect of certain cancer therapies.
• Broader opportunities in pain, anxiety disorders, dermatologic conditions, inflammation, and oncology where lipid-signaling and endocannabinoid pathways may be relevant.

Regulatory and Capital Markets Context

Artelo is a smaller reporting company under U.S. securities regulations and has used equity offerings, warrants, and convertible notes to fund its operations and pipeline. The company has filed registration statements, including a Form S-1 related to the resale of shares underlying convertible notes and warrants, and has completed underwritten public offerings and private placements as described in its Form 8-K and registration filings.

In an 8-K dated November 25, 2025, Artelo disclosed that it received a Nasdaq delist determination letter relating to non-compliance with Nasdaq Listing Rule 5550(b)(1) concerning minimum stockholders’ equity. The company reported its intention to appeal the determination to a Nasdaq hearing panel, and indicated that its common stock would continue to trade on Nasdaq under the symbol ARTL during the appeal process, subject to Nasdaq’s procedures.

Research Collaborations and Scientific Positioning

Artelo’s disclosures reference collaborations with academic researchers and technology partners. Peer-reviewed publications partially funded by the company, including work from laboratories at the University of Western Ontario and other institutions, have examined the effects of Artelo’s compounds on stress-induced anxiety and depression behaviors, hippocampal neurogenesis, and endocannabinoid-related signaling pathways in preclinical models. These studies support the company’s focus on indirect modulation of the endocannabinoid system through FABP inhibition and on pharmaceutical-grade CBD compositions.

Through conference presentations and scientific publications, Artelo has outlined its intent to pursue multiple therapeutic opportunities with its FABP inhibitor portfolio, including pain and oncology indications, while advancing ART27.13 and ART12.11 in supportive care and neuropsychiatric contexts.

Corporate Governance and Shareholder Actions

Artelo’s SEC filings describe various corporate governance and capital structure actions, including:

• Amendments to its bylaws addressing notice periods for board meetings, shareholder action by written consent, and record date provisions.
• A reverse stock split effected through a Certificate of Change to its Articles of Incorporation.
• A special meeting of stockholders approving an increase in authorized common shares and considering, but not approving, a substantial increase in authorized preferred shares.
• Cooperation and standstill agreements with certain shareholders, including voting commitments and ownership limitations.

These actions reflect the company’s efforts to manage its capital structure, maintain exchange listing standards, and address shareholder and governance matters while pursuing its clinical development plans.

Summary

In summary, Artelo Biosciences, Inc. is a Nasdaq-listed, clinical-stage biopharmaceutical company focused on lipid-signaling and endocannabinoid system modulation. Its publicly described pipeline includes ART27.13 for cancer-related anorexia and weight loss, ART26.12 as a FABP5 inhibitor for chemotherapy-induced peripheral neuropathy and other potential indications, ART12.11 as a patented CBD-TMP cocrystal with enhanced pharmaceutical properties, and a broader FABP inhibitor platform aimed at oncology and other diseases linked to dysregulated lipid metabolism. The company positions its programs to address areas of high unmet need in oncology supportive care, pain, mood and stress-related disorders, dermatology, and inflammation, while actively managing its regulatory, governance, and capital markets profile.